Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension
Biomolecules · 2024
DOI: 10.3390/biom14091187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Jason Shirian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-2, Matrix Metalloproteinase 9. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Matrix metalloproteinases (MMPs) are significant drivers of many diseases, including cancer, and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties for drug candidates, such as complete MMP inhibition, low toxicity, low immunogenicity, and high tissue permeability. However, a major challenge with TIMPs is their rapid clearance from the bloodstream due to their small size. This study explores a method for extending the plasma half-life of the N-terminal domain of TIMP2 (N-TIMP2) by appending it with a long, intrinsically unfolded tail containing Pro, Ala, and Thr (PATylation). We designed and produced two PATylated N-TIMP2 constructs with tail lengths of 100 and 200 amino acids (N-TIMP2-PAT100 and N-TIMP2-PAT200). Both constructs demonstrated higher apparent molecular weights and retained high inhibitory activity against MMP-9. N-TIMP2-PAT200 significantly increased plasma half-life in mice compared to the non-PATylated variant, enhancing its therapeutic potential. PATylation offers distinct advantages for half-life extension, such as fully genetic encoding, monodispersion, and biodegradability. It can be easily applied to N-TIMP2 variants engineered for high affinity and selectivity toward individual MMPs, creating promising candidates for drug development against MMP-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL 32224, USA.
ORCID-Profile: Jason Shirian, Matt Coban, Matt L Pawlush, Evette S Radisky, Julia M Shifman
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NIH R01CA258274
- US-Israel Binational Science Foundation (BSF)
- Israel Science Foundation
- ICRF
- NIH R01 GM132100
Zitieren
APA
Shirian, J., Hockla, A., Gleba, J. J., Coban, M., Rotenberg, N., Strik, L. M., Alasonyalilar Demirer, A., Pawlush, M. L., Copland, J. A., Radisky, E. S., & Shifman, J. M. (2024). Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension. Biomolecules. https://doi.org/10.3390/biom14091187
Vancouver
Shirian J, Hockla A, Gleba JJ, Coban M, Rotenberg N, Strik LM, et al. Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension. Biomolecules. 2024. doi:10.3390/biom14091187
BibTeX
@article{Shirian2024,
author = {Shirian, Jason and Hockla, Alexandra and Gleba, Justyna J and Coban, Matt and Rotenberg, Naama and Strik, Laura M and Alasonyalilar Demirer, Aylin and Pawlush, Matt L and Copland, John A and Radisky, Evette S and Shifman, Julia M},
title = {Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14091187}
}
EUVIMED